Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Cytomegalovirus Stories

2011-02-16 10:56:00

RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Chimerix's broad spectrum antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release. CMX001 is a potential dual-use therapeutic with evidence of...

2011-02-14 07:30:00

DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures. Proceeds from...

2011-02-10 03:32:00

LONDON, February 10, 2011 /PRNewswire/ -- - Leading Collaboration Between Cell Medica, Leukaemia & Lymphoma Research, University of Birmingham and NHS Blood and Transplant Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London. The...

8bfe344dba09574de5187c940d51ce1a
2011-02-08 08:48:52

New experiments at the University of California, Berkeley, may one day lead to anti-viral treatments that involve swallowing Salmonella bacteria, effectively using one bug to stop another. Researchers at UC Berkeley's School of Public Health have reprogrammed Salmonella, the same foodborne pathogen that can cause diarrhea, fever and abdominal cramps, to safely transport virus-stopping enzymes into cells without causing disease. Not only did this technique effectively treat mice infected with...

2011-01-07 07:30:00

RESEARCH TRIANGLE PARK, N.C., Jan. 7, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses. Under the expanded-access protocol developed in conjunction with the U.S. Food and Drug Administration...

9e20c58084628f3b8a552d6cea3f1f821
2010-11-29 06:40:08

Young people who are overexposed to antibacterial soaps containing triclosan may suffer more allergies, and exposure to higher levels of Bisphenol A among adults may negatively influence the immune system, a new University of Michigan School of Public Health study suggests. Triclosan is a chemical compound widely used in products such as antibacterial soaps, toothpaste, pens, diaper bags and medical devices. Bisphenol A (BPA) is found in many plastics and, for example, as a protective lining...

2010-11-22 08:00:00

RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that data demonstrating preclinical efficacy of Chimerix's lead antiviral compound CMX001 against herpes simplex virus (HSV) as well as its ability to penetrate the blood-brain barrier was published in the November 15, 2010 issue of The Journal of Infectious Diseases(1). The paper, "Efficacy of CMX001 Against Herpes...

2010-11-19 08:00:00

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2010 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Piper Jaffray 22nd Annual Health Care Conference on December 1, 2010 at 11:50 a.m. ET in New York City. Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a...

2010-11-17 08:00:00

GENEVA and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented an update to the World Health Organization (WHO) on the development of the company's lead antiviral compound, CMX001, at the 12th Meeting of the WHO Advisory Committee on Variola Virus Research in a presentation titled "Status of CMX001 for Smallpox and Other dsDNA Viruses." CMX001 is being developed for...

2010-11-16 13:27:00

NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2010 /PRNewswire/ -- Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism. These data, presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC...


Latest Cytomegalovirus Reference Libraries

0_bbd337098cfaf28eafeb5f5f010e48ef
2011-01-12 15:30:34

Cytomegalovirus, a herpes viral genus, is known in humans as HCMV. It is part of the Betaherpesvirinae subfamily. Other herpesviruses fall into the subfamilies of Alphaherpesvirinae or Gammaherpesvirinae. xHCMV infections are frequently associated with salivary glands. It can be lethal for people who are immunocompromised. Other CMV viruses are found in several mammal species, but species isolated from animals differ from HCMV in terms of genomic structure. HCMV is found all over the...

More Articles (1 articles) »